Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 277.90M | 232.34M | 183.03M | 90.09M | 14.56M |
| Gross Profit | 181.72M | 163.76M | 124.33M | 54.95M | 7.09M |
| EBITDA | 21.87M | -68.50M | -167.31M | -183.34M | -206.19M |
| Net Income | -13.62M | -94.01M | -200.38M | -195.82M | -216.08M |
Balance Sheet | |||||
| Total Assets | 1.21B | 1.20B | 1.31B | 1.50B | 773.63M |
| Cash, Cash Equivalents and Short-Term Investments | 713.72M | 721.14M | 870.12M | 1.22B | 632.42M |
| Total Debt | 35.75M | 36.38M | 50.69M | 41.94M | 24.69M |
| Total Liabilities | 144.00M | 125.60M | 147.08M | 132.10M | 82.60M |
| Stockholders Equity | 1.06B | 1.08B | 1.17B | 1.37B | 681.37M |
Cash Flow | |||||
| Free Cash Flow | -8.39M | -137.72M | -304.01M | -260.33M | -90.42M |
| Operating Cash Flow | -3.23M | -88.41M | -266.77M | -205.85M | -74.81M |
| Investing Cash Flow | 10.80M | -125.45M | 44.84M | -161.10M | -4.53M |
| Financing Cash Flow | -12.38M | -21.48M | -24.75M | 821.25M | 686.22M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$9.07B | 38.53 | 6.49% | ― | 0.87% | -18.05% | |
60 Neutral | HK$18.32B | 5.55 | -4.00% | 3.32% | 9.92% | -18.97% | |
58 Neutral | HK$1.83B | ― | -27.82% | ― | -6.12% | 0.43% | |
55 Neutral | €5.87B | ― | -10.43% | ― | 36.76% | 42.89% | |
53 Neutral | HK$2.19B | ― | -1.28% | ― | 17.45% | 85.71% | |
51 Neutral | HK$3.40B | ― | -2.19% | ― | 5.32% | 89.43% |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare Medical Technology Corporation Limited has announced the convening of its 2025 second extraordinary general meeting (EGM) to be held on August 29, 2025. The primary agenda is to consider and approve the utilization of the company’s capital reserve to offset significant losses amounting to RMB575,082,245.74. This move is in accordance with the company’s Articles of Association and relevant laws, indicating a strategic financial decision aimed at stabilizing the company’s financial standing.
Shanghai HeartCare Medical Technology Corporation Limited announced a positive profit alert, expecting a net profit of not less than RMB40 million for the first half of 2025, marking a significant turnaround from a net loss in the same period of 2024. This improvement is attributed to business growth and a decrease in the expense ratio. Additionally, the company proposes to utilize its capital reserve to offset losses, pending shareholder approval at an upcoming extraordinary general meeting.
Shanghai Heartcare Medical Technology Corp. Ltd. announced a change in its supervisory committee with the appointment of Mr. Liu Hongbao as the new Employee Representative Supervisor. This change follows the resignation of Mr. Liu Baiwei due to personal work arrangements, who also served as the Chairman of the Supervisory Committee. The company expressed gratitude for Mr. Liu Baiwei’s contributions and clarified that there are no disagreements or pending claims related to his resignation. Mr. Liu Hongbao, who has extensive experience in sales and marketing of medical devices, will not receive remuneration for his role as Employee Representative Supervisor.
Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from July 30, 2025, to August 29, 2025, to determine shareholders eligible to attend and vote at the 2025 second extraordinary general meeting scheduled for August 29, 2025. This move is significant for shareholders as it dictates the timeline for share transfers and eligibility to participate in the company’s decision-making process during the EGM.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
Shanghai HeartCare Medical Technology Corp. Ltd. successfully held its 2024 Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) on May 26, 2025, where all proposed resolutions were passed by poll. The meetings were conducted in compliance with the Company Law of the PRC and the Articles of Association, with significant shareholder participation, indicating robust governance and stakeholder engagement.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.
Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.